Wedge Capital Management L L P NC Boosts Holdings in Thermo Fisher Scientific Inc. $TMO

Wedge Capital Management L L P NC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,859 shares of the medical research company’s stock after acquiring an additional 1,012 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Thermo Fisher Scientific were worth $9,147,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of TMO. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Lafayette Investments Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock worth $376,000 after buying an additional 22 shares during the last quarter. Challenger Wealth Management increased its position in Thermo Fisher Scientific by 3.1% during the 2nd quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock worth $298,000 after purchasing an additional 22 shares in the last quarter. Security National Bank of Sioux City Iowa IA grew its stake in shares of Thermo Fisher Scientific by 0.3% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock valued at $2,655,000 after buying an additional 22 shares in the last quarter. Finally, Armstrong Advisory Group Inc. grew its position in shares of Thermo Fisher Scientific by 2.3% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 1,039 shares of the medical research company’s stock worth $504,000 after acquiring an additional 23 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.8%

Shares of NYSE TMO opened at $567.01 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company’s fifty day moving average is $569.01 and its 200-day moving average is $498.06. The stock has a market cap of $213.03 billion, a price-to-earnings ratio of 32.76, a P/E/G ratio of 4.21 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the previous year, the firm earned $5.28 earnings per share. The company’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has approved a share repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Frederick M. Lowery sold 6,912 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total value of $4,022,369.28. Following the transaction, the executive vice president owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. This represents a 32.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the transaction, the vice president directly owned 13,087 shares in the company, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 149,271 shares of company stock worth $86,507,282 in the last ninety days. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. Leerink Partners upped their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. UBS Group upped their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Finally, Argus raised their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $616.60.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.